Since the formation of the BioLife Solutions – SAVSU Technologies biologistex joint venture in the fourth quarter of 2014, the companies have submitted 13 other patent applications related to novel innovations incorporated into current, or to be incorporated into future, precision thermal shipping containers under the evo brand. This includes models that precisely maintain biologic payload temperature stability across the entire shipping continuum; including -196°C liquid nitrogen dry vapor shippers, -80°C dry ice shippers, and 2° - 8°C and controlled room temperature (CRT) shippers using conditioned phase change insulating materials. These patent applications also include claims related to the evo is Cold Chain Software as a Service (SaaS) live cell visibility platform.
Bruce McCormick commented, "We are pleased to receive this notice of allowance of what we believe will be a series of granted patent applications we filed to protect our growing intellectual property estate. We believe our hardware and software innovations, embodied in current and future evo models, will offer significant value to the growing regenerative and personalized medicine markets."
Mike Rice, BioLife CEO, remarked, "This notice of allowance is another validation of the vision SAVSU and BioLife formed several years ago, with a focused and intentional goal to improve cold chain logistics of cell and gene therapies. We believe the advanced and innovative evo hardware and software technologies will have tremendous impact on the preservation, delivery, and quality management of these precious, time and temperature sensitive biologic medicines."
SAVSU is a leading designer and manufacturer of innovative high-performance cloud-connected passive storage and transport containers for temperature sensitive biologics and pharmaceuticals.
BioLife Solutions is the leading developer, manufacturer and supplier of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media for cells and tissues.
Savsu, biolife increase evo ip estate, allowance of new us patent, cold chain technologies